Risk factors associated with candidaemia in the neonatal intensive care unit: a case-control study.
The incidence of candidaemia is steadily increasing in neonatal intensive care units (NICUs). Several neonatal risk factors for candidaemia have been identified, however, the number of cases in controlled studies is small and knowledge concerning maternal and perinatal risk factors is limited. The present study attempted to identify modifiable, independent maternal, perinatal and neonatal risk factors for candidaemia using a retrospective case-control study in the NICU of a tertiary-care paediatric medical centre. The study group consisted of 56 neonates admitted to the NICU between 1996 and 2000 who acquired candidaemia. The control group comprised the first infant admitted immediately after each study infant matched for gestational age (+/-10 days) and birthweight (+/-200 g). Potential maternal, perinatal and neonatal risk factors were compared between the groups using statistical methods and analysed by univariate and multivariate stepwise logistic regression models. The independent risk factors found to be significantly associated with increased risk of candidaemia were duration of ventilation and presence of bacteraemia before candidaemia. Maternal steroids had a significant protective effect. The positive predictive value using these three parameters was 78.38%. Maximizing in-utero steroid treatment in high-risk pregnancies, minimizing the days of mechanical ventilation and investment of efforts in prevention of bacteraemia may help to reduce the incidence of candidaemia in the NICU.
Linder
N
N
Department of Neonatal Intensive Care, Schneider Children's Medical Center of Israel, Petah Tikva 49202, Israel. linderm@netvision.net.il
Levit
O
O
Klinger
G
G
Kogan
I
I
Levy
I
I
Shalit
I
I
Ashkenazi
S
S
Sirota
L
L
D000704:Analysis of Variance; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000150:complications; D001724:Birth Weight; D002177:Candidiasis / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D003428:Cross Infection / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D004363:Drug Utilization; D016469:Fungemia / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D005865:Gestational Age; D006776:Hospitals, Pediatric; D006801:Humans; D015994:Incidence; D007231:Infant, Newborn; D017053:Infection Control / Q000379:methods / Q000592:standards; D007363:Intensive Care Units, Neonatal / Q000706:statistics & numerical data*; D007557:Israel / Q000453:epidemiology; D016015:Logistic Models; D011237:Predictive Value of Tests; D012121:Respiration, Artificial / Q000009:adverse effects; D012307:Risk Factors; D013997:Time Factors
D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000935:Antifungal Agents